Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

79.55EUR
12:36pm EDT
Change (% chg)

€0.33 (+0.42%)
Prev Close
€79.22
Open
€79.00
Day's High
€79.55
Day's Low
€78.89
Volume
2,030,858
Avg. Vol
2,381,674
52-wk High
€80.44
52-wk Low
€62.88

Select another date:

Mon, Mar 18 2019

Photo

Exclusive: Sanofi says working on CEO succession plan

PARIS Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday.

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

March 11 The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs.

Taxotere plaintiff urges MDL judge to keep bellwether case against Sanofi intact

A woman suing Sanofi S.A. for allegedly failing to warn her and her doctor about the risk of permanent hair loss from breast cancer drug Taxotere on Wednesday sharply disputed the company's contention that she would have been prescribed the drug anyway.

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

UPDATE 2-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

CORRECTED-UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report

Feb 25 A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

CORRECTED-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Philippines revokes Sanofi's product license for dengue vaccine

MANILA The Philippines has permanently halted the sale, distribution and marketing of Sanofi's dengue vaccine in the country after the French drug maker failed to meet the directives of regulators.

Select another date: